Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with a Neutral at Baird. 2. L3Harris Technologies (LHX) initiated with an Overweight at Alembic Global. 3. Phathom Pharmaceuticals (PHAT) was initiated with a Buy at Jefferies and Needham and a Neutral at Goldman Sachs. 4. Cabaletta Bio (CABA) initiated with an Outperform at Cowen and Evercore ISI as well as an Overweight at Morgan Stanley. 5. Agenus (AGEN) resumed with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Consensus is $21.17B.

Consensus is $12.71. 2024 adjusted segment operating margin guidance increases from ~15% to greater than 15%.

Reports Q1 revenue $5.21B, consensus $5.11B. "We're off to a strong start to 2024, reporting solid revenue with higher operating margin across all four segments and our Trusted Disruptor strategy continues to drive demand for innovative, resilient and mission-critical solutions aligned with national security needs. We delivered double-digit top line growth while continuing to drive improvements to operational and program performance," said Christopher E. Kubasik, Chair and CEO.